Milan, February 1, 2017 – Portolano Cavallo announces that attorneys Marco Blei and Elisa Stefanini have joined the firm as associates in the Life Sciences practice group. In particular, Marco will focus on Intellectual Property and IT matters, Elisa with regulatory issues. Both professionals come from BonelliErede, where they were members of the “Healthcare and Life Sciences” Focus Team.
In welcoming the new associates, Francesco Portolano commented: “As previously announced, we aim to replicating in the Life Sciences sector our leadership in the Digital/Technology matters. In 2016, Portolano Cavallo was already recognized in the field of Life Sciences, thanks to our experience in legal issues arising at the crossroads between Life Sciences and technology. Today, we continue our Life Sciences focused growth with two sector experts, who have long been working together: Elisa adds significant regulatory expertise and Marco brings additional strength to our intellectual property track record. In this way, we can offer to Life Sciences players full gamut legal assistance: from R&D of products and devices, to contracts, litigation and transactions and regulatory matters”.
In his fifteen-year IP, IT and Privacy experience, Marco has assisted several players in the pharmaceutical, and medical devices sector and other Life Sciences players, both in contentious and non-contentious matters. His expertise includes: drafting and negotiation of development, use, enhancement, and intellectual property granting and acquisition agreements; pharmaceuticals production, supply, distribution and co-marketing agreements, as well as contracts governing clinical trials and proctoring; assistance in litigation concerning patents, trademarks, design, copyrights and unfair competition; and, assistance on matters of misleading advertisement and unfair commercial practices.
Elisa has a twelve-year Life Sciences regulatory experience, including in: human clinical trials and release to the market, promotion and marketing of pharmaceutical drugs and medical devices. She has also honed significant experience relating to the protection of personal information in clinical trials, with special focus on the processing of genetic data, including through biobanks. She also frequently advised on Life Sciences regulatory issues in M&A transactions carried out by some of the most important Italian and international players.
